All posts tagged: Research

CC Community News Digest (May 25-31)

Assorted news from the last week: FDA issues its final guidance on the RACE Act and specifies when sponsors must conduct pediatric studies for new cancer drugs as well as when those requirements can be waived or deferred. CAC2 Supporting Organization Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, went public and announced the pricing of its initial public offering of 10,000,000 shares of its common stock. Findings from an analysis of patients’ cognitive functioning after treatment of specific extracranial solid tumors [...] Read more

Liquid Biopsy for Early Cancer Detection in Patients with Cancer Predisposition Syndromes

In April's CAC2 All-Member Webinar, Dr. Brian D. Crompton (pediatric oncologist at Dana Farber/Boston Children's Hospital) and CAC2 Member Greg Harper (Living LFS) presented about the possibilities with emerging technology identifying circulating cancer cells with liquid biopsies, using Li-Fraumeni Syndrome as a case study. The presentation below described the investigation into a liquid biopsy for Li-Fraumeni Syndrome patients and the EDISYN consortium and how nonprofits partnering with medical research centers to help empower patients and families. Read more

CC Community News Digest (March 29-April 11)

Assorted news from the last week: From the American Cancer Society:  Prevalence and predictors of cancer‐related worry and associations with health behaviors in adult survivors of childhood cancer From Children’s Cause:  Rachel McCallum is a long-term survivor diagnosed with Anaplastic Astrocytoma of the 4th ventricle of the brain stem in 1993.  Her experience as a long-term survivor has encouraged her to become an advocate for others like herself who have struggled with the transition from pediatric patient to independent adulthood. Research from St. Jude suggests that the socioeconomics of families is a significant predictor of whether childhood brain tumor survivors […]

Read more

CC Community News Digest (December 21-January 3)

Assorted news from the last two weeks: NCI unveiled two new resources for young people with cancer: tips to help young people facing end-of-life decisions talk with their doctors and make choices about palliative care, advance directives, living wills, and how they want to be remembered. resource to help young people find support after a cancer diagnosis and during cancer treatment. It includes advice on talking with mental health experts, spotting signs of depression, and finding support groups. Study suggests “that children in the U.S. may be treated more intensely compared to children in the U.K., which led to a decreased […]

Read more

CC Community News Digest (November 23-29)

Assorted news from the last week: CAC2 Member Carolyn Breinich explains how her personal experience with childhood cancer and a fortuitous meeting with Mariah Forster Olson at the 2019 CAC2 Summit led them to a friendship and a partnership in Better Together. Y-mAbs Therapeutics, Inc. has received U.S. Food and Drug Administration (FDA) approval for a new treatment option for a certain type of neuroblastoma. A consortium of researchers delved into the molecular details of 218 pediatric brain tumors, analyzing the genes, proteins, and RNA transcription that allow these cancers to proliferate. This analysis, which identified a number of unique [...] Read more

CC Community News Digest (November 16-22)

Assorted news from the last week: Data from an ongoing Phase 1 Pacific Pediatric Neuro-Oncology Consortium (PNOC) network study sponsored by the Dana-Farber Cancer Institute showed that patients under 18 years of age with relapsed low-grade glioma that had been treated with DAY101 had notable responses:  Of the eight patients with RAF fusions, two patients achieved a complete response by Response Assessment for Neuro-Oncology (RANO), three had a partial response, and three achieved prolonged stable disease. The median time to response for these patients was only 10.5 weeks, and the most common side effects were skin rash and hair color […]

Read more

20 Years of Neuroblastoma Research Progress

Have you wondered what has driven the progress in treating relapsed and refectory neuroblastoma patients?  If so, you may be interested in watching our November All-Member Webinar.  CAC2 Member Gavin Lindberg (EVAN Foundation) hosted a speaker program that included Drs. Kate Matthay, Judy Villablanca, and Steve DuBois speaking on:  20 Years of Neuroblastoma Research Progress. These leaders of the New Approaches to Neuroblastoma Therapy (NANT) consortium informed the audience about the progress and challenges associated with developing new strategies for refractory and relapsed neuroblastoma patients. We also learned about the history of this 20 year-old, multi-institution network, their collaborations with the Children’s [...] Read more

CC Community News Digest (October 26-November 1)

Assorted news from the last week: Children with birth defects who were conceived via in vitro fertilization (IVF) were more likely to develop childhood cancer compared to those conceived naturally, according to the results of a cohort study originating at Michigan State University. The likelihood of cancer survivors developing a new, unrelated malignancy is “about 10 to 20 percent higher” than someone in the general population. The insurance dropout rate among adolescents and young adult cancer survivors may have been lowered due to the dependent coverage provision in the Affordable Care Act, according to the findings of a new study […]

Read more

CC Community News Digest (October 19-25)

Assorted news from the last week: The International Cancer Research Partnership (ICRP) published results from its Impact of Covid-19 on childhood cancer research funding organizations survey More news about the effect of Covid-19 on cancer research (all types, not just pediatric and AYA). A team of scientists at Texas A&M University have developed a way to more accurately both detect and monitor a common type of pediatric brain cancer, setting the stage for giving clinicians a real-time view into how the cancer responds to treatment. Researchers at the University of Michigan have demonstrated that a new liquid biopsy approach overcomes traditional barriers to [...] Read more

Pediatric Cancer Data Commons: A Story of Impact and Promise

Have you heard of the ways in which data science is advancing pediatric cancer research?  You may be interested in watching our October All-Member Webinar. CAC2 Member Mariah Forster Olson (Neuroblastoma Cancer research Foundation) introduced Dr. Sam Volchenboum, who spoke about his work leading the Pediatric Cancer Data Commons at the University of Chicago Medicine.  During the presentation Volchenboum highlighted the ways in which data science is advancing pediatric cancer research and discussed how this work can be influential for cancer survivors.  He was gracious enough to answer the many questions posed by our members. Dr. Volchenboum graciously allowed us [...] Read more